TW219330B - - Google Patents

Download PDF

Info

Publication number: TW219330B
Authority: TW; Taiwan
Prior art keywords: patent application; compound; item; tablets; hours
Prior art date: 1990-12-21

Application number

TW080110140A

Other languages

English (en)

Chinese (zh)

Original Assignee

Glaxo Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-21

Filing date

1991-12-26

Publication date

1994-01-21

1990-12-21 Priority claimed from GB909027827A external-priority patent/GB9027827D0/en

1991-12-26 Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa

1994-01-21 Application granted granted Critical

1994-01-21 Publication of TW219330B publication Critical patent/TW219330B/zh

Links

150000001875 compounds Chemical class 0.000 claims description 43
239000000203 mixture Substances 0.000 claims description 22
238000005187 foaming Methods 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 19
239000008187 granular material Substances 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
239000003826 tablet Substances 0.000 claims description 13
239000004480 active ingredient Substances 0.000 claims description 11
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 8
239000000843 powder Substances 0.000 claims description 8
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 7
239000012453 solvate Substances 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
239000000018 receptor agonist Substances 0.000 claims description 6
229940044601 receptor agonist Drugs 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
229910052770 Uranium Inorganic materials 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
239000003205 fragrance Substances 0.000 claims description 5
239000007937 lozenge Substances 0.000 claims description 5
-1 polypropylene Polymers 0.000 claims description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
239000004615 ingredient Substances 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
238000005266 casting Methods 0.000 claims description 3
230000001568 sexual effect Effects 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
239000004743 Polypropylene Substances 0.000 claims description 2
150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims description 2
239000000314 lubricant Substances 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
229920001155 polypropylene Polymers 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 2
235000019640 taste Nutrition 0.000 claims description 2
230000036470 plasma concentration Effects 0.000 claims 5
239000000047 product Substances 0.000 claims 5
239000007938 effervescent tablet Substances 0.000 claims 4
239000007864 aqueous solution Substances 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 2
239000011888 foil Substances 0.000 claims 2
238000005070 sampling Methods 0.000 claims 2
235000018185 Betula X alpestris Nutrition 0.000 claims 1
235000018212 Betula X uliginosa Nutrition 0.000 claims 1
241000283690 Bos taurus Species 0.000 claims 1
GTWWQCWMCOETPA-UHFFFAOYSA-F C([O-])([O-])=O.[Ta+5].[Au+3].C([O-])([O-])=O.C([O-])([O-])=O.C([O-])([O-])=O Chemical compound C([O-])([O-])=O.[Ta+5].[Au+3].C([O-])([O-])=O.C([O-])([O-])=O.C([O-])([O-])=O GTWWQCWMCOETPA-UHFFFAOYSA-F 0.000 claims 1
235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
235000009685 Crataegus X maligna Nutrition 0.000 claims 1
235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
235000009486 Crataegus bullatus Nutrition 0.000 claims 1
235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
235000009682 Crataegus limnophila Nutrition 0.000 claims 1
235000004423 Crataegus monogyna Nutrition 0.000 claims 1
240000000171 Crataegus monogyna Species 0.000 claims 1
235000002313 Crataegus paludosa Nutrition 0.000 claims 1
235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
229910052692 Dysprosium Inorganic materials 0.000 claims 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
208000004350 Strabismus Diseases 0.000 claims 1
235000011941 Tilia x europaea Nutrition 0.000 claims 1
238000005299 abrasion Methods 0.000 claims 1
229910052789 astatine Inorganic materials 0.000 claims 1
RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims 1
239000008280 blood Substances 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
RIHNLVPJQUBCET-UHFFFAOYSA-N butanedioic acid;1h-indol-5-ylmethanesulfonamide Chemical compound OC(=O)CCC(O)=O.NS(=O)(=O)CC1=CC=C2NC=CC2=C1 RIHNLVPJQUBCET-UHFFFAOYSA-N 0.000 claims 1
230000015556 catabolic process Effects 0.000 claims 1
239000012141 concentrate Substances 0.000 claims 1
238000000354 decomposition reaction Methods 0.000 claims 1
238000006731 degradation reaction Methods 0.000 claims 1
239000006185 dispersion Substances 0.000 claims 1
238000010494 dissociation reaction Methods 0.000 claims 1
230000005593 dissociations Effects 0.000 claims 1
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
238000009434 installation Methods 0.000 claims 1
238000002386 leaching Methods 0.000 claims 1
239000004571 lime Substances 0.000 claims 1
239000001384 succinic acid Substances 0.000 claims 1
239000013589 supplement Substances 0.000 claims 1
235000019605 sweet taste sensations Nutrition 0.000 claims 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 7
108010011485 Aspartame Proteins 0.000 description 6
239000003513 alkali Substances 0.000 description 6
239000000605 aspartame Substances 0.000 description 6
235000010357 aspartame Nutrition 0.000 description 6
229960003438 aspartame Drugs 0.000 description 6
235000003599 food sweetener Nutrition 0.000 description 6
239000003765 sweetening agent Substances 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
206010019233 Headaches Diseases 0.000 description 5
231100000869 headache Toxicity 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
208000019695 Migraine disease Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000000556 agonist Substances 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
206010027599 migraine Diseases 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000003752 saphenous vein Anatomy 0.000 description 3
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
235000010234 sodium benzoate Nutrition 0.000 description 3
239000004299 sodium benzoate Substances 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
235000000832 Ayote Nutrition 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102100032487 Beta-mannosidase Human genes 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
235000009854 Cucurbita moschata Nutrition 0.000 description 1
240000001980 Cucurbita pepo Species 0.000 description 1
235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
241000446313 Lamella Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241000218206 Ranunculus Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000008548 Tension-Type Headache Diseases 0.000 description 1
YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
229960005164 acesulfame Drugs 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
108010055059 beta-Mannosidase Proteins 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002079 cooperative effect Effects 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
210000003128 head Anatomy 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000015136 pumpkin Nutrition 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
238000007789 sealing Methods 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
PORMUFZNYQJOEI-UHFFFAOYSA-N sumatriptan succinate Chemical compound OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 PORMUFZNYQJOEI-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW080110140A 1990-12-21 1991-12-26 TW219330B (2)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909027827A GB9027827D0 (en)	1990-12-21	1990-12-21	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
TW219330B true TW219330B (2)	1994-01-21

Family

ID=51347993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW080110140A TW219330B (2)	1990-12-21	1991-12-26

Country Status (2)

Country	Link
TW (1)	TW219330B (2)
UA (1)	UA27784C2 (2)

1991
- 1991-12-17 UA UA93004332A patent/UA27784C2/uk unknown
- 1991-12-26 TW TW080110140A patent/TW219330B/zh active

Also Published As

Publication number	Publication date
UA27784C2 (uk)	2000-10-16

Publication	Publication Date	Title
JP3778518B2 (ja)	2006-05-24	苦味薬剤の味の良い水性液体組成物
US5811436A (en)	1998-09-22	Oral liquid compositions containing paroxetine resinate
JP4074675B2 (ja)	2008-04-09	トラマドール又はトラマドール塩の急速に崩壊する薬剤形
NO175131B (no)	1994-05-30	Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin
BR112012022873B1 (pt)	2021-09-14	Composição farmacêutica para administração oral compreendendo brometo de metilnaltrexona e dodecil sulfato de sódio
US5468504A (en)	1995-11-21	Effervescent pharmaceutical compositions
EP1177788A2 (en)	2002-02-06	Pharmaceutical composition of fluoxetin in coated dispersible tablets and process for its manufacture
JPH07112973B2 (ja)	1995-12-06	イブプロフェン又はその塩を活物質とする可溶性の消炎性組成物及びその製造方法
WO2023193745A1 (zh)	2023-10-12	一种右美沙芬奎尼丁口崩片及其应用
US6726928B2 (en)	2004-04-27	Process for preparing solid dosage forms for unpalatable pharmaceuticals
AU2002313364B2 (en)	2004-02-19	Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith
TWI286072B (en)	2007-09-01	Sleeping medicine formed by coating solid
JPH01246221A (ja)	1989-10-02	フエノール含有鎮咳液体組成物
TW219330B (2)	1994-01-21
KR100417200B1 (ko)	2004-02-05	세트랄린 경구 농축물
JP4564749B2 (ja)	2010-10-20	新規乾燥及び水性エピナスチン−シロップ製剤
KR100188172B1 (ko)	1999-06-01	제약 조성물
CN114569742B (zh)	2022-07-19	一种组合物及其制备方法和应用
US4241047A (en)	1980-12-23	Novel medicinal composition for the treatment of biliary lithiasis
JPH09501680A (ja)	1997-02-18	Ｈ▲下２▼−アンタゴニストの経口組成物
EP0574624B1 (en)	1997-09-10	Pharmaceutical compositions
CN119280152A (zh)	2025-01-10	一种地氯雷他定口服溶液及其制备方法
CN1823770A (zh)	2006-08-30	一种复方右美沙芬口腔崩解片
MXPA96003140A (en)	1997-12-01	Rapid desintegration medicine based on detramadol or a trama salt
NO179996B (no)	1996-10-21	Brusede preparater inneholdende 5HT1-lignende reseptorantagonister